Reply on Clinical Outcomes for Urological Cancer Patients
Author Information
Author(s): Olmos D, Arkenau H-T, Ang J E, de Bono J S, Judson I, Kaye S B
Primary Institution: The Institute of Cancer Research and The Royal Marsden Hospital
Conclusion
The study suggests that chemotherapy-naive patients with castration-resistant prostate cancer may have better outcomes when treated with active agents.
Supporting Evidence
- 66% of the castration-resistant prostate cancer patients were chemotherapy-naive.
- Previous studies showed a median overall survival benefit of 2.5 months for chemotherapy-naive patients treated with docetaxel.
- Many patients received abiraterone acetate, which has shown promising activity.
Takeaway
This study looks at how well certain cancer patients do when they get new treatments before or after standard chemotherapy.
Methodology
The study analyzed outcomes of chemotherapy-naive and chemotherapy-pretreated patients in a phase I trial.
Limitations
The small sample sizes in the subgroups limit the reliability of the findings.
Participant Demographics
The study included 54 patients with castration-resistant prostate cancer, of which 37 were chemotherapy-naive.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website